These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 2847461)

  • 21. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin.
    Young E; Wells P; Holloway S; Weitz J; Hirsh J
    Thromb Haemost; 1994 Mar; 71(3):300-4. PubMed ID: 8029793
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low molecular weight heparin for the out-of-hospital treatment of venous thrombosis: rationale and clinical results.
    Hirsh J; Crowther M
    Thromb Haemost; 1997 Jul; 78(1):689-92. PubMed ID: 9198240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of venous thromboembolic disease. The impact of low-molecular-weight heparin.
    Tapson VF; Hull RD
    Clin Chest Med; 1995 Jun; 16(2):281-94. PubMed ID: 7656540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Therapy of thromboses with low-molecular-weight heparins].
    Haas S; Haas P
    Wien Med Wochenschr; 1999; 149(2-4):39-45; discussion 45. PubMed ID: 10378321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Postoperative monitoring of low molecular weight heparin prophylaxis in high-risk patients.
    Bacher P; Horst B; Breyer HG; Hoppensteadt DA; Walenga JM; Fareed J
    Semin Thromb Hemost; 1993; 19 Suppl 1():73-8. PubMed ID: 8395735
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prophylaxis of postoperative deep vein thrombosis in general surgery: experiences with Fragmin.
    Bergqvist D
    Acta Chir Scand Suppl; 1988; 543():87-9. PubMed ID: 2847463
    [No Abstract]   [Full Text] [Related]  

  • 27. [Prevention of thromboembolism in hysterectomies with low molecular weight heparin Fragmin].
    Briel RC; Doller P; Hermann CP
    Geburtshilfe Frauenheilkd; 1988 Mar; 48(3):160-4. PubMed ID: 2836259
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A double-blind randomized placebo controlled trial of thromboprophylaxis in major elective general surgery using once daily injections of a low molecular weight heparin fragment (Fragmin).
    Ockelford PA; Patterson J; Johns AS
    Thromb Haemost; 1989 Dec; 62(4):1046-9. PubMed ID: 2559484
    [TBL] [Abstract][Full Text] [Related]  

  • 29. From unfractionated heparins to low molecular weight heparins.
    Hirsh J
    Acta Chir Scand Suppl; 1990; 556():42-50. PubMed ID: 1705072
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Low molecular weight heparin: favorable effect profile for prevention and therapy of venous thrombosis].
    Marbet GA
    Ther Umsch; 1992 Dec; 49(12):843-9. PubMed ID: 1336627
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Why low molecular weight heparin?
    Mammen EF
    Semin Thromb Hemost; 1990 Oct; 16 Suppl():1-4. PubMed ID: 1962897
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Evaluation of the effectiveness and safety of Fragmin (Kabi 2165) versus calcium heparin in the prevention of deep venous thrombosis in general surgery].
    Creperio G; Marabini M; Ciocia G; Bergonzi M; Fincato M
    Minerva Chir; 1990 Sep; 45(17):1101-6. PubMed ID: 2177861
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Meta-analysis on randomized trials comparing the results of low-molecular weight heparins to those of fractioned heparins in the prevention of deep venous thrombosis].
    Daures JP; Schved JF; Momas I; Gril JC; Azoulay P; Gremy F
    Rev Epidemiol Sante Publique; 1989; 37(4):363-9. PubMed ID: 2558404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement.
    Planes A; Vochelle N; Mazas F; Mansat C; Zucman J; Landais A; Pascariello JC; Weill D; Butel J
    Thromb Haemost; 1988 Dec; 60(3):407-10. PubMed ID: 2853459
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical potential of low molecular weight heparins.
    Levine MN; Hirsh J
    Baillieres Clin Haematol; 1990 Jul; 3(3):545-54. PubMed ID: 2176904
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Current status of low molecular weight heparin].
    Maillet P
    Phlebologie; 1992; 45(2):179-83. PubMed ID: 1326773
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The relationship between ex vivo anti-factor Xa levels and efficacy/safety of low molecular weight heparin.
    Turpie AG
    Br J Clin Pract Suppl; 1989 Jan; 65():18-23; discussion 23-5. PubMed ID: 2554949
    [No Abstract]   [Full Text] [Related]  

  • 38. [Pharmacologic and clinical principles for rational anti-thrombotic preventive treatment with low molecular weight heparin].
    Pindur G; Köhler M; Heiden M; Leipnitz C; Rupp KH; Wenzel E
    Langenbecks Arch Chir Suppl II Verh Dtsch Ges Chir; 1990; ():1149-55. PubMed ID: 1983502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Treatment of deep venous thrombosis with low molecular weight heparin (Fragmin)].
    Nesvold A; Ly B; Abildgaard U; Stiris M
    Tidsskr Nor Laegeforen; 1991 Nov; 111(27):3296-7. PubMed ID: 1659751
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The new heparins].
    Samama M; Babinet-Berthier A
    J Mal Vasc; 1992; 17(2):91-106. PubMed ID: 1319447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.